Nu Skin achieved a dramatic financial turnaround with revenue growing 49% to $3.2B and swinging from a $146.6M net loss to $160.2M profit, though this was accompanied by concerning operational cash flow decline and reduced share count.
This represents a remarkable operational turnaround that suggests either successful restructuring or potential acquisition activity given the magnitude of changes. However, the 28% decline in operating cash flow despite strong profitability improvement raises questions about earnings quality and cash conversion efficiency that investors should scrutinize.
Nu Skin delivered exceptional top-line growth with revenue jumping 49% to $3.2B while achieving a stunning $307M improvement in net income from deep losses to solid profitability. The company strengthened its balance sheet significantly, reducing total liabilities by 27% and boosting stockholders' equity by 24%, while cash positions improved substantially. However, the 28% decline in operating cash flow despite strong earnings growth, combined with nearly doubled interest expenses, suggests the transformation may have come at the cost of cash generation efficiency and increased leverage.
Net income grew 209.3% — bottom-line growth signals improving overall business health.
Operating leverage kicking in — revenue growth outpacing cost growth, a hallmark of scaling businesses.
Interest expense surged 89.6% — significant debt increase or rising rates materially impacting earnings.
Strong top-line growth of 49% — accelerating demand or successful expansion into new markets.
Operating cash flow softened — monitor whether temporary working capital timing or structural deterioration.
Cash grew 27.7% — improving liquidity position supports investment and shareholder returns.
Liabilities reduced 26.6% — deleveraging improves balance sheet strength and financial flexibility.
Equity base grew 23.6% — retained earnings accumulation or equity issuance strengthening the balance sheet.
Receivables declined — improved collection efficiency or conservative revenue recognition.
R&D spending cut 16.9% — could signal cost discipline or concerning reduction in innovation investment.
See what changed in your portfolio's filings
500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.
Try Tracenotes free →